Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksACRL.L Regulatory News (ACRL)

  • There is currently no data for ACRL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Temporary Suspension of Trading

5 Oct 2017 07:00

RNS Number : 7536S
Accrol Group Holdings PLC
05 October 2017
 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Accrol Group Holdings plc

Trading Update and Temporary Suspension of Trading on AIM

 

Trading Update

Accrol Group Holdings plc (the "Company" or "Accrol"), the AIM-listed leading independent tissue converter, provides an update on current trading for the financial year to 30 April 2018.

The Company is currently experiencing more challenging trading conditions which are having a significant effect on the trading performance of the Company for FY18. These factors are likely to have less of an impact on the Company's trading performance in FY19.

The challenges currently faced are set out below.

· Continued increases in input costs are being driven by parent reel price inflation. In particular, there has recently been a further material rise in parent reel prices.

· The anticipated inflation recovery through product price increases has delivered less than planned to date. In addition, the delay in price increases will have a reduced positive impact on the current financial year.

· The Company has also incurred higher than anticipated costs in relation to the operational changes associated with preparing the business for growth. The Company believes these changes will deliver improved performance over the longer term.

· The Board has recently been advised that a Health and Safety incident, which occurred prior to the Company's AIM IPO, may now result in a more significant fine being imposed by the Health and Safety Executive (HSE) than was previously anticipated. Whilst this is not expected to impact on trading, based on advice received by the Company's legal advisers, any resulting fine may have a material impact on the Company's cash position.

Whilst the revenue expectations for FY18 remain broadly in line with market expectations, the Board has reviewed its expectations of the Group's performance. Based on current market conditions, the Board now anticipates that earnings will be significantly below existing market forecasts for the current financial year, and as a consequence net debt will be correspondingly higher at year end.

In view of the above, the Board will review the dividend in respect of the current financial year.

Following the appointment of Gareth Jenkins as CEO on 11 September 2017, the Board commenced a wide-ranging review of the Company's operations with a view to improving its margins and its overall financial performance.

Temporary Suspension of Trading on AIM

Whilst the Board considers the anticipated impact of the above on the Company's net debt position, pending clarification of its financial circumstances, the Company has applied for suspension of trading in the Company's ordinary shares on AIM with effect from 7:30 a.m. today.

 

For further information please contact:

Zeus Capital Limited (Nominated Adviser & Joint Broker) 

Dan Bate / Andrew Jones

Tel: +44 (0) 161 831 1512

Dominic King / John Goold

Tel: +44 (0) 20 3829 5000

 

Liberum Capital Limited (Joint Broker)

Clayton Bush / Chris Clarke/ Lucy Sharma / Dominik Götzenberger

Tel: +44 (0) 20 3100 2222

 

Camarco (Media enquiries) 

Jennifer Renwick / Kimberley Taylor

Tel: +44 (0) 203 757 4994

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGBUUUPMPWC
Date   Source Headline
27th Jan 20231:27 pmRNSTR-1
24th Jan 20237:00 amRNSHalf Year Results
24th Jan 20237:00 amRNSStrategic Review Outcomes
11th Jan 20237:00 amRNSNotice: Results, Strategic Review & Presentations
20th Dec 20227:00 amRNSDirector Dealing
28th Nov 20221:36 pmRNSLaunch of second ESG Report
21st Nov 20227:00 amRNSHalf Year Trading Update
18th Nov 20227:00 amRNSAwards under LTIP and PDMR dealing
18th Oct 20221:27 pmRNSResult of 2022 Annual General Meeting
23rd Sep 20227:38 amRNSNotice of AGM and Posting of Annual Report 2022
20th Sep 20224:41 pmRNSSecond Price Monitoring Extn
20th Sep 20224:36 pmRNSPrice Monitoring Extension
6th Sep 20227:00 amRNSAudited Final Results
10th Aug 20227:00 amRNSNotice of Final Results and Online Presentations
31st May 202212:21 pmRNSTR-1
17th May 20227:00 amRNSTrading Update - FY22 in line with expectations
10th May 202211:57 amRNSTR-1
7th Apr 20227:00 amRNSTR-1
15th Mar 20223:58 pmRNSTR-1
14th Mar 20227:00 amRNSUpdate on LTC Share Purchase Agreement
11th Mar 20224:41 pmRNSSecond Price Monitoring Extn
11th Mar 20224:36 pmRNSPrice Monitoring Extension
4th Mar 20227:00 amRNSDirector Dealing
24th Feb 20223:45 pmRNSTR-1
24th Feb 20227:00 amRNSAwards under LTIP and PDMR dealing
11th Feb 202212:40 pmRNSTR-1
3rd Feb 20221:59 pmRNSTR-1
2nd Feb 202211:08 amRNSTR-1
21st Jan 20222:42 pmRNSTR-1
18th Jan 20227:00 amRNSHalf Year Results
17th Jan 20226:18 pmRNSTR-1
17th Jan 20223:13 pmRNSTR-1
12th Jan 20227:00 amRNSTrading Update
16th Dec 20217:00 amRNSNotice of Results and Online Investor Presentation
20th Oct 20217:00 amRNSTrading Update
28th Sep 20219:46 amRNSLaunch of ESG Report
24th Sep 202111:59 amRNSResult of AGM
27th Aug 20211:32 pmRNSNotice of AGM and Posting of Annual Report 2021
28th Jul 20215:30 pmRNSTR-1
23rd Jul 20212:35 pmRNSDirector Share Purchase
23rd Jul 20212:31 pmRNSExercise of Options, Director Dealings and TVR
16th Jul 20214:37 pmRNSDirector Shareholding
14th Jul 20217:00 amRNSAudited Final Results
7th Jul 20217:00 amRNSNotice of Results and Online Investor Presentation
4th Jun 202110:38 amRNSTR-1
18th May 20214:41 pmRNSSecond Price Monitoring Extn
18th May 20214:36 pmRNSPrice Monitoring Extension
18th May 20212:06 pmRNSSecond Price Monitoring Extn
18th May 20212:00 pmRNSPrice Monitoring Extension
18th May 202111:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.